摘要
随着精准医学的发展,针对儿童晚期恶性实体瘤的免疫治疗和分子靶向药物治疗已开始应用于临床。以原肌球蛋白受体激酶(tropomyosin-receptor kinase,TRK)抑制剂拉罗替尼和恩曲替尼为代表的靶向治疗药物对各类神经营养因子受体酪氨酸激酶(neurotrophin tyrosine receptor kinase,NTRK)基因融合阳性表达的儿童晚期恶性实体瘤具有较高的有效性和安全性,标志着"儿童泛肿瘤靶向药物时代"的到来。本文旨在介绍此类药物的作用机制及其临床应用研究进展。
With a rapid development of precision medicine,immunotherapy and molecular targeted drug dosing for advanced malignant solid tumors have been applied in children.Among them,the effectiveness and safety of TRK inhibitors larotrectinib and entrectinib in children with advanced malignant solid tumors with positive expressions of various NTRK fusion genes marks the arrival of the era of pan-tumor targeted drugs for children.This review focused upon the mechanisms and clinical research advances of these drugs.
作者
吴晔明
Wu Yeming(Department of Pediatric Surgery,Hangzhou Children’s Hospital,Huangzhou 310005,China)
出处
《临床小儿外科杂志》
CAS
CSCD
2023年第7期607-610,共4页
Journal of Clinical Pediatric Surgery
关键词
受体酪氨酸激酶样孤儿受体
肿瘤
分子靶向治疗
外科手术
儿童
Receptor Tyrosine Kinase-like Orphan Receptors
Neoplasms
Molecular Targeted Therapy
Surgical Procedures
Operative
Child
